

# Davina Gherzi

## List of Publications by Year in descending order

Source: <https://exaly.com/author-pdf/7042947/publications.pdf>

Version: 2024-02-01

25  
papers

10,543  
citations

567281  
15  
h-index

677142  
22  
g-index

25  
all docs

25  
docs citations

25  
times ranked

18529  
citing authors

#	ARTICLE	IF	CITATIONS
1	A collaborative approach to adopting/adapting guidelines. The Australian 24-hour movement guidelines for children (5-12 years) and young people (13-17 years): An integration of physical activity, sedentary behaviour, and sleep. International Journal of Behavioral Nutrition and Physical Activity, 2022, 19, 2.	4.6	42
2	A Reporting Tool for Adapted Guidelines in Health Care: The RIGHT-Ad@pt Checklist. Annals of Internal Medicine, 2022, 175, 710-719.	3.9	16
3	Guidelines for Reporting Trial Protocols and Completed Trials Modified Due to the COVID-19 Pandemic and Other Extenuating Circumstances. JAMA - Journal of the American Medical Association, 2021, 326, 257.	7.4	168
4	919Step-by-step guidance on prospective meta-analyses. International Journal of Epidemiology, 2021, 50, .	1.9	0
5	Protocol for the development of guidance for stakeholder engagement in health and healthcare guideline development and implementation. Systematic Reviews, 2020, 9, 21.	5.3	92
6	Prospective meta-analyses and Cochrane's role in embracing next-generation methodologies. The Cochrane Library, 2020, 10, ED000145.	2.8	2
7	Selecting, refining and identifying priority Cochrane Reviews in health communication and participation in partnership with consumers and other stakeholders. Health Research Policy and Systems, 2019, 17, 45.	2.8	26
8	GRADE guidelines for environmental and occupational health: A new series of articles in Environment International. Environment International, 2019, 128, 11-12.	10.0	17
9	Extending the RIGHT statement for reporting adapted practice guidelines in healthcare: the RIGHT-Ad@pt Checklist protocol. BMJ Open, 2019, 9, e031767.	1.9	17
10	The risk of bias in observational studies of exposures (ROBINS-E) tool: concerns arising from application to observational studies of exposures. Systematic Reviews, 2018, 7, 242.	5.3	146
11	Research priorities in health communication and participation: international survey of consumers and other stakeholders. BMJ Open, 2018, 8, e019481.	1.9	58
12	Sharing and reuse of individual participant data from clinical trials: principles and recommendations. BMJ Open, 2017, 7, e018647.	1.9	116
13	A collaborative approach to adopting/adapting guidelines - The Australian 24-Hour Movement Guidelines for the early years (Birth to 5 years): an integration of physical activity, sedentary behavior, and sleep. BMC Public Health, 2017, 17, 869.	2.9	261
14	GRADE: Assessing the quality of evidence in environmental and occupational health. Environment International, 2016, 92-93, 611-616.	10.0	194
15	Special collection on Indigenous health. Medical Journal of Australia, 2015, 203, 242-242.	1.7	0
16	Can Australia's clinical practice guidelines be trusted?. Medical Journal of Australia, 2015, 202, 8-8.	1.7	6
17	Preferred reporting items for systematic review and meta-analysis protocols (PRISMA-P) 2015: elaboration and explanation. BMJ, The, 2015, 349, g7647-g7647.	6.0	8,367
18	Taxane-containing regimens for metastatic breast cancer. The Cochrane Library, 2015, , CD003366.	2.8	78

#	ARTICLE	IF	CITATIONS
19	Research translation and chronic illness. Medical Journal of Australia, 2014, 201, 312-312.	1.7	0
20	Increasing value and reducing waste: addressing inaccessible research. Lancet, The, 2014, 383, 257-266.	13.7	692
21	The Quality of Registration of Clinical Trials: Still a Problem. PLoS ONE, 2014, 9, e84727.	2.5	111
22	The future of institutional review boards. Lancet Oncology, The, 2004, 5, 325-329.	10.7	10
23	Antitumour antibiotic containing regimens for metastatic breast cancer. The Cochrane Library, 2004, , CD003367.	2.8	15
24	Chemotherapy or Endocrine Therapy for Metastatic Breast Cancer?. Breast Cancer Research and Treatment, 2003, 81, 53-56.	2.5	11
25	Chemotherapy alone versus endocrine therapy alone for metastatic breast cancer. The Cochrane Library, 2003, , CD002747.	2.8	98